NovoCure (NVCR) Q3 2024 earnings summary

Executive summary

• Net revenues reached $155.1 million in Q3 2024, up 22% year-over-year, driven by launches in France, improved U.S. approval rates, and record 4,113 active patients on therapy.

• FDA approved Optune Lua (LUNAR) for metastatic non-small cell lung cancer, with U.S. commercial launch underway and plans for global expansion.

• CEO transition announced: Ashley Cordova to succeed Asaf Danziger in January 2025, with Christoph Brackmann as new CFO and new COO appointed.

• Advanced clinical pipeline with key milestones in pancreatic and brain metastases trials, including PANOVA-3 and PANOVA-4.

• FDA Breakthrough Device designation granted for TTFields therapy in brain metastases from NSCLC.

Financial highlights

• Net revenues: $155.1 million, up 22% year-over-year; U.S. contributed $98.3 million, Germany $17.0 million, France $15.2 million, Japan $8.6 million.

• Gross margin improved to 77% from 75% year-over-year, attributed to higher net revenue per patient and strong performance in France.

• Adjusted EBITDA was $1.7 million for Q3 2024, positive for the second consecutive quarter.

• Net loss for Q3 2024 was $30.6 million ($0.28 per share), improved from $49.5 million in Q3 2023.

• Cash, cash equivalents, and short-term investments totaled $959.9 million as of September 30, 2024.

Outlook and guidance

• Top-line data from the PANOVA-3 pancreatic cancer trial expected in Q4 2024; additional trial data in 2026.

• Gross margin expected to face headwinds from next-generation arrays and lung cancer launch, but to normalize within 6–8 quarters.

• Cash and investments are expected to fund operations for at least the next 12 months.

• Reimbursement for lung cancer indication anticipated to take 1–2 years, with initial focus on private payers before Medicare.

• No expectation for recurring benefit from $4.7 million in U.S. prior period claims revenue.